Prognosis
Gilead’s Remdesivir Becomes First Virus Treatment to Win FDA Nod
- Hospital patients who got treatment recovered five days faster
- Antiviral medicine hasn’t been shown to reduce Covid-19 deaths
This article is for subscribers only.
The U.S. Food and Drug Administration approved Gilead Sciences Inc.’s antiviral therapy remdesivir on Thursday, making it the first drug to obtain formal clearance for treating the coronavirus.
Regulators had granted an emergency-use authorization for remdesivir earlier this year, and since then the drug has become a widely used therapy in hospitalized Covid-19 patients. It was given to President Donald Trump this month when he was diagnosed with the virus.